Biologic selection guided by epigenetic markers in Crohn's disease
Part of Digestive system clinical trials.
This trial compares two different ways to choose your Crohn's treatment: one based on a special test of your cells (epigenetic markers) and the other based on standard care. It aims to see which approach works better for people with moderate to severe Crohn's disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You have a confirmed diagnosis of Crohn's disease in the small intestine, colon, or both.
- Your Crohn's is currently moderate to severe (your doctor will confirm this).
- You have not been treated with vedolizumab or ustekinumab before, and you've had no more than one other biologic or JAK inhibitor.
- You are not pregnant or breastfeeding, and you agree to use birth control if needed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a medicine called tirzepatide to see if it can help people with active Crohn’s disease who have not responded to multiple prior treatments. It focuses on how the drug might work beyond just reducing inflammation.
This trial compares how well different combinations of drugs calm inflammation in the gut compared to single drugs. It uses tissue samples taken during a colonoscopy to see which approach works best for people with inflammatory bowel disease.
This trial tests a personalized approach to starting anti-TNF therapy—a common treatment for inflammatory bowel disease (IBD)—in patients who have never taken it before. The goal is to help doctors choose the right anti-TNF medication and dose based on each patient's individual characteristics.
This Phase 4 trial tests which type of biologic medicine works best as the first treatment for people with moderate-to-severe Crohn’s that mainly affects the ileum. It may help you and your care team choose a more effective first option, based on which strategy leads to better control of symptoms and intestinal inflammation.
This study tests whether adding a special diet (called CDED) to a biologic medicine (infliximab or adalimumab) helps control Crohn's disease better than the medicine alone. It may reduce inflammation and improve symptoms.
This trial tests new targeted therapies for adults with moderate to severe Crohn's disease that hasn't improved with standard treatments. The goal is to see if these drugs can reduce inflammation and improve symptoms.
Hear when a new Crohn Disease (CD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.